Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Affymax, Takeda Recall Omontys Injection | Contract Pharma

What are you searching for?

Sign in
Breaking News

Affymax, Takeda Recall Omontys Injection

Postmarketing reports show serious hypersensitivity reactions

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. have voluntarily recalled all lots of OMONTYS (peginesatide) Injection as a result of postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis. The companies have been working with the FDA and issued a letter to health care professionals indicating that no new or existing patients should receive OMONTYS, which is indicated for the treatment of anemia due to chronic kidney disease.
 
To date, fatal reactions have been reported in approximately 0.02% of patients following the first dose of intravenous administration. The reported serious hypersensitivity reactions occurred within 30 minutes after administration. There have been no reports of such reactions following subsequent dosing, or in patients who have completed their dialysis session.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters